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treatment; 1 had an ileostomy. Two patients (25%) required 
prolonged admission, 1 was admitted to critical care with 
neutropenic colitis. Capecitabine was discontinued in 6/8 
(75%); 5 (63%) required a break in XRT. Two patients (25%) 
discontinued XRT altogether. Mean small bowel V45 for 
patients who did and did not develop G3 toxicity was 38.6 
cm3 (range 0 – 178.8) and 113.0 cm3 (38.4 – 222.4) 
respectively. Two patients had a small bowel V45 >195 cm3, 
both developed G3 bowel toxicity. 
 
Conclusion: In this series, incidence of G3 bowel toxicity in 
patients receiving chemoradiotherapy for rectal cancer was 
not influenced by gender, age, pre-treatment bowel habit or 
body habitus. PTV size, patient positioning and radiotherapy 
delivery technique did not alter the risk. Patients who 
developed G3 toxicity had a larger volume of small bowel 
receiving ≥45 Gy. Based on this, we now routinely calculate 
dose to small bowel, thus identifying patients who are at 
higher risk of developing G3 toxicity and review or change 
the treatment plan, including chemotherapy dose, to 
mitigate this risk. 
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Purpose or Objective: The past decade in rectal cancer 
research has raised questions about complete pathological 
response (pCR) after neoadjuvant therapy. In this context, 
there has been much hype to identify patients with clinical 
complete response (cCR) who could eventually be candidates 
for nonoperative cancer care. So far, experts have published 
stringent criteria to define cCR, which remain to be validated 
with surveillance strategies. The purpose of our study is to 
review pathological mucosal changes after neoadjuvant 
combined chemoradiation therapy (CRT) for rectal cancer. 
 
Material and Methods: This retrospective review was 
conducted in a tertiary referral center. Histopathology 
reports were retrieved for rectal cancer patients treated 
with neoadjuvant CRT. Exclusion criteria included recurrent 
rectal cancer, stage IV disease, rectal cancer in the context 
of IBD or FAP, patient enrollment under clinical trials with 
chemotherapy or other treatment schemes, and patients who 
were not operated. The macroscopic mucosal appearance of 
the specimen was compared with the final pathological 
staging.  
 
Results: Eighty-eight patients met our inclusion criteria and 
had complete staging and pathological data with gross 
mucosal descriptions. These included 59 male and 29 female 
patients with a median age of 63 years (range 29-83). The 
staging proportions were: 3.4% stage cI, 15.9% stage cII, and 
80.7% stage cIII; 93.2% of patients were cT3/cT4 and 75% 
were cN+. Clinical CRM was involved in 30 patients. All 
patients were treated with neoadjuvant CRT consisting of 45 
Gy in 25 fractions to the pelvis with a tumour bed boost of 
5.4 Gy in 3 fractions using 3D conformal radiotherapy; 
chemotherapy was 5-FU based. Total mesorectal excision 
(TME) was performed in all patients. The median time 
between the last day of radiotherapy and surgery was 58 days 
(range 32-308). As a result, 15 patients (17.0%) were staged 
as ypT0N0 (pCR); 12 patients (13.6%) remained CRM+ on 
surgical pathology evaluation. Eighty-seven patients (98.9%) 
had residual mucosal abnormalities incompatible with cCR: 
most changes seen were ulceration and, less often, stenosis. 
Of the 70 patients with microscopic residual tumor, 7 
patients had no macroscopic tumor visualized but an ulcer in 
its place. There was no statistically significant association 
between time from CRT to surgery and pCR. 
 
Conclusion: Most patients undergoing neoadjuvant CRT have 
residual mucosal abnormalities two months after CRT. There 
are needs to define criteria for clinical endoscopic evaluation 
to define cCR. 
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Purpose or Objective: The association between metabolism 
and cancer has been recently emphasized. This study aimed 
to find the prognostic significance of obesity in advanced 
stage rectal cancer patients treated with surgery and 
radiotherapy (RT). 
 
Material and Methods: We retrospectively reviewed the 
medical records of 111 patients who were treated with 
combined surgery and RT for clinical stage II-III (T3 or N+) 
rectal cancer between 2008 and 2014. The prognostic 
significance of obesity (body mass index ≥25 kg/m2, 
according to Asian classification) in local control was 
evaluated. 
 
Results: The median follow-up was 27.3 months (range, 3.3–
82.1 months). Twenty-five patients (22.5%) were classified as 
obese. Treatment failure occurred in 33 patients (29.7%), 
including local failures in 13 patients (11.7%), regional lymph 
node failures in 5, and distant metastases in 24. The 3-year 
local control, recurrence-free survival, and overall survival 
rates were 88.6%, 72.6%, and 87.3%, respectively. Obesity 
(n=25) significantly reduced the local control rate (p=0.049, 
3-year local control 75.8%), especially in women (n=37, 
p=0.026). Segregation of local control was best achieved by 
body mass index of 25.6 as a cutoff value. 
 
Conclusion: Obese rectal cancer patients showed poor local 
control after combined surgery and RT. More effective local 
treatment strategies for obese patients are warranted. 
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Purpose or Objective: To report long-term follow-up data 
and determine the toxicity rate in patients with locally 
advanced rectal cancer (LARC) treated with intensified neo-
adjuvant regimen. 
 
Material and Methods: Patients with histologically proven 
adenocarcinoma of the rectum, stage III-IV, were included 
and treated with a tri-modality approach. Baseline patient 
characteristics are shown in Table 1.  
Intensified neo-adjuvant treatment (CRT) consisted of RT 
total dose of 50.4/54 Gy and concomitant OXP (50 mg/m2/ 
week) and 5-FU (200 mg/m2/ five daily continuous infusion). 
Surgery was planned 7-9 weeks after the end of CRT. 
Adjuvant chemotherapy was recommended in those patients 
with lymph-node metastasis at diagnosis. 
 
Results: One hundred patients (median age 64 years) were 
eligible, between January 2007 and December 2014. Overall, 
the 5-years OS and DFS were 76.4% and 74.5%, respectively. 
Local recurrence was recorded in 9 patients (9%) and 23 
patients (23%) presented distant metastasis. CRT was well 
tolerated, with only 17% grade 3/4 acute toxicity. Twenty-
four patients (24%) had a pathologic complete response (pCR) 
and only 1 patient peri-operative metastasis. The 5-year OS 
rate was 95.7% for patients with pCR and 70.4% without pCR 
(p = 0.0489). The 5-year DFS were 95.7% and 66.7% for pCR 
and no-pCR tumor histology, respectively (p=0.0275) 
(Figure1). 
 
